Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

RHEUMATOLOGY IN PERSPECTIVE · RHEUMAVIEW

SJÖGREN’S · Systemic treatment

Choosing systemic treatment in Sjögren’s disease

From the affected organ to the therapeutic mechanism, evidence and next decision

The clinically useful question is not simply which drug treats Sjögren’s. It is which intervention addresses the lesion that is active in this patient, quickly enough to preserve function and with an acceptable burden. Inflammatory arthritis, vasculitic neuropathy, interstitial lung disease and renal tubular dysfunction are not interchangeable treatment indications.

This chapter develops the treatment choices introduced in the target-and-response guide. It covers the principal adult systemic pathways, explains where evidence is direct or extrapolated, and separates maintenance decisions from urgent organ protection. It is not a universal prescribing protocol. Core evidence reviewed: 22 September 2026. Trial evidence updated: 11 November 2026. Immunoglobulin decision supplement clinically reviewed: 9 October 2026. Detailed glandular care and ACA overlap have their own linked chapters.

The treatment map starts with the lesion

Name the organ, mechanism, severity and trajectory before selecting a drug. “Pulmonary involvement” is insufficient if the actual problem could be bronchiectasis, inflammatory interstitial disease, progressive fibrosis, infection or pulmonary vascular disease. “Neuropathy” is insufficient when small-fiber pain and rapidly evolving multifocal axonal loss lead to different decisions.

Established problemTherapeutic directionOutcome that matters
Persistent inflammatory synovitisJoint-directed DMARD treatment; assess RA overlapSwelling, inflammatory symptoms and useful joint function
Immune-mediated peripheral nerve injuryPhenotype-specific immune therapy plus pain and rehabilitation careFurther neurological loss, strength, sensation, balance and function
Clinically important Sjögren-associated ILDImmunosuppression according to activity, severity and trajectoryLung physiology, symptoms, oxygen needs and imaging course
Progressive pulmonary fibrosisReassess immune treatment and consider an antifibrotic pathwaySlowing further decline; not restoration of normal lung tissue
Active tubulointerstitial nephritisSelected immune therapy plus correction of tubular disturbancesRenal function and electrolyte/acid–base control
Suspected immune-complex glomerular diseaseEstablish pathology and drivers; coordinate renal and systemic treatmentKidney preservation, proteinuria and control of the systemic process

These directions summarize different evidence bases rather than rank drugs against one another. They must be read with the phenotype-specific sections below. The general Sjögren recommendations and organ guidelines support this approach, but many systemic decisions still depend on low-certainty evidence. [R01] [R02] [R03] [R04] [R05]

Back to contents ↑

Read the evidence before importing the recommendation

Four questions prevent much therapeutic overstatement: who was studied, what lesion they had, what outcome changed and what comparison was actually made. A change in systemic activity is not proof of reversal of a particular neuropathy. Improvement after treatment in a small renal series is not a randomized estimate of benefit. A CTD-ILD trial may contain few or no Sjögren patients in an analyzable subgroup.

“Strong recommendation” and “high-certainty efficacy evidence” also describe different things. The PNS guideline (first published online 2025; 2026 issue) sometimes makes a strong recommendation despite very-low-certainty evidence because irreversible loss and the consequences of inaction influence the decision. That reasoning should be visible when discussing treatment. Conversely, a conditional recommendation does not mean that the disease is unimportant. [R03]

Guideline dates require care. The BSR document appeared online in 2024 and in a 2025 issue, but its main search ended in 2022. It remains useful for conventional management, yet cannot be treated as a complete account of trials published in 2026. New evidence must be added without silently rewriting what the older guideline actually recommended. [R01] [R09]

November trial update: monthly ianalumab improved mean ESSDAI in NEPTUNUS, without significant key responder or symptom differences. OASIZ-301 reported significant systemic-activity improvement with dazodalibep and a dryness benefit for the every-four-week regimen. In contrast, phase III efgartigimod UNITY was discontinued for futility. These are different drugs, populations and reporting levels; none provides a universal organ-rescue protocol. [N01] [N02] [N03] See the clinical-trial archive for the comparisons and limitations.

Back to contents ↑

Joints and muscles: demonstrate the inflammatory target

Distinguish arthralgia, synovitis, tenosynovitis, mechanical pain and widespread pain amplification. Examine the symptomatic distribution, swelling and function; use imaging when it resolves an actual uncertainty. Morning stiffness or a positive rheumatoid factor alone does not establish the mechanism of every painful joint. Persistent erosive inflammatory arthritis should prompt careful assessment for associated RA rather than automatic attribution to a generic Sjögren phenotype.

HCQ can have a selected role; the limitations of its symptom-trial evidence are discussed in the linked target-and-response chapter. For significant inflammatory arthritis, methotrexate is an established clinical option supported by Sjögren guidance despite limited Sjögren-specific trial evidence. The basis is different from a claim that MTX reliably restores salivary function. Treatment of confirmed RA overlap follows the associated inflammatory joint disease as well as the Sjögren context. [R01] [R02]

Do not turn a symptom-only assessment into an automatic sequence from HCQ to MTX to a biologic. If joint inflammation is controlled but pain persists, reconsider structural, tendon, neuropathic and nociplastic contributors. Pain relief, rehabilitation and immune treatment can address different parts of the same presentation.

True muscle weakness deserves localization. Myalgia is not myositis. Evaluate objective weakness and relevant muscle investigations, while considering steroid myopathy, electrolyte disturbance and neurological causes. Sjögren can coexist with a separate inflammatory myopathy or inclusion body myositis; the treatment expectations are not interchangeable. A new inability to rise or climb stairs should therefore change the diagnostic question before it automatically increases the DMARD dose. [R01]

Back to contents ↑

Skin and vessels: a rash is not one phenotype

Photodistributed inflammatory lesions, hypergammaglobulinemic purpura, cryoglobulinemic vasculitis, urticaria, drug reactions and infection can look superficially related while requiring different decisions. Record morphology, distribution, duration, symptoms and systemic findings. Dermatological review and a properly selected biopsy can distinguish a cutaneous inflammatory target from a vascular lesion or another process.

Treatment of limited skin inflammation may rely on local measures or a selected systemic agent. Persistent or severe vasculitis requires assessment beyond the skin: urinalysis and renal function, neurological findings, complements, cryoglobulins and the broader clinical context may change urgency. A cryoglobulin result is sensitive to collection and handling; an unexpected negative result should be interpreted with the laboratory method and clinical findings.

B-cell-directed treatment can be appropriate for selected severe systemic complications, including cryoglobulinemic disease, but “purpura” alone is too imprecise to justify a regimen. Skin-limited lesions without organ injury and progressive neuropathy with renal findings are different risk states. A confirmed clonal or infectious driver changes the treatment partnership and may change the regimen. [R01] [R02] [R03]

Raynaud’s and ischemia require a vascular assessment. Vasospasm treatment is not equivalent to immune suppression. New painful persistent digital discoloration, ulceration or threatened tissue loss should not be handled simply by increasing a routine Sjögren medicine. ACA with established SSc requires the overlap-specific precautions discussed in its own chapter. [R12]

Back to contents ↑

Peripheral nerves: separate pain relief from immune rescue

Localize the neuropathy and determine whether the course is stable, progressive or aggressive. Burning pain with a normal nerve-conduction study can still reflect small-fiber disease; a normal large-fiber test does not settle that question. In contrast, painful asymmetric weakness, foot drop or multifocal loss raises concern for a different and potentially urgent process. Alternative causes and their treatment remain relevant even in a patient with well-established Sjögren.

The PNS guideline separates symptomatic medication from immune treatment. Gabapentinoids or an SNRI are options for neuropathic pain. Choice should account for renal function, sedation, falls and other medicines; anticholinergic adverse effects are particularly relevant when considering a tricyclic in someone with marked sicca. Symptom relief does not establish control of active nerve injury. [R03]

For immune-mediated nonvasculitic large-fiber disease, or selected recent, severe or progressive small-fiber disease inadequately controlled symptomatically, IVIG may be considered. This is not a recommendation to give immunoglobulin to every person with tingling. Sensory ganglionopathy with significant manifestations and suspected vasculitic neuropathy have more urgent immune-treatment pathways. For the latter, the guideline prioritizes glucocorticoids with rituximab, with cyclophosphamide considered after an inadequate first-line response; IVIG is not its default initial treatment. The evidence remains very low certainty. [R03]

Follow objective loss and patient function alongside pain. A patient can have less pain but continuing weakness; another can have controlled inflammation with persistent neuropathic pain from prior injury. Each finding changes the next decision differently. Rehabilitation, orthoses and protection of insensate areas are part of preserving function, not evidence that immune therapy was abandoned.

Back to contents ↑

Autonomic dysfunction needs physiological characterization

Orthostatic tachycardia, orthostatic hypotension, gastrointestinal dysmotility and altered sweating are not one measurement. Relate symptoms to position, meals, temperature, medicines and daily function. Check postural physiology and obtain specialist testing when it is needed to characterize the disorder. Other causes of autonomic symptoms should be considered rather than assuming that the Sjögren label explains every episode.

Initial treatment can include medication review, compression and individualized fluid, salt or activity measures. Fluid and salt advice must account for hypertension, heart failure, kidney disease and other restrictions. Heart-rate control, support of vascular tone and volume expansion address different physiological problems; they are not interchangeable prescriptions for all dizziness.

The PNS guidance reserves consideration of immune escalation for selected severe, progressive, immune-mediated dysfunction that has not responded adequately to symptom-directed measures. An IVIG pathway and, in selected refractory cases, rituximab are described with very-low-certainty support. The presence of nonspecific dizziness or fatigue alone does not establish that indication. [R03]

Use a concrete functional outcome and an objective physiological baseline where possible. “Still dizzy” may conceal improvement in one trigger and persistence of another; a heart-rate measurement alone may not describe how long the person can remain upright. Both are relevant to a useful follow-up decision.

Back to contents ↑

Interstitial lung disease: activity, fibrosis and progression

Confirm the ILD phenotype and its trajectory using HRCT, pulmonary physiology and clinical context. A decline needs explanation: infection, pulmonary vascular disease, aspiration, airway disease, drug toxicity and measurement variation can complicate interpretation. HRCT pattern informs the discussion, but a pattern label alone does not establish how rapidly the disease is changing or how much is reversible.

The ACR/CHEST guideline conditionally includes mycophenolate, azathioprine, rituximab and cyclophosphamide among first-line SARD-ILD options. This does not prove equal efficacy in Sjögren or require that all patients receive the same sequence. ERS/EULAR supports immunosuppression for Sjögren-associated ILD while explicitly recognizing very-low-certainty, substantially indirect evidence. Clinical severity, extrapulmonary disease, reproductive plans, prior infection and treatment feasibility help choose among options. [R04] [R05]

Direct Sjögren data are much smaller than the broad treatment lists imply. A retrospective cohort included 19 patients; seven received MMF and seven AZA, with overlapping exposure to other therapy. Associations between treatment and lung-function trajectories are useful signals, but treatment selection, limited numbers and absence of randomization prevent a reliable head-to-head ranking. [R07]

Nintedanib addresses a progressive fibrotic pathway. ACR/CHEST recommends against its routine first-line use for Sjögren-ILD, whereas ERS/EULAR supports considering it for progressive pulmonary fibrosis. These statements concern different clinical situations. An antifibrotic is not a general treatment for cough, a substitute for treating infection, or proof that all inflammatory therapy should stop. [R04] [R05]

Follow the lesion and the treatment burden together. Stabilization may be clinically worthwhile when prior decline was documented, yet cannot prove individual drug causality. Worsening breathlessness despite stable FVC requires a broader assessment rather than an automatic declaration of either treatment success or failure.

Back to contents ↑

Airway disease and cough need a parallel pathway

Persistent cough can reflect airway dryness, bronchial hyperreactivity, small-airway disease, bronchiectasis, reflux/aspiration or infection. ILD is only one possibility. The investigation should follow the symptom pattern and clinical findings, with pulmonary testing and imaging when indicated. A previously normal chest radiograph does not answer every one of these questions.

For established airway disease, bronchodilator or inhaled anti-inflammatory treatment, airway clearance and infection-directed care may be more relevant than increasing systemic immune therapy. The pulmonary consensus describes these phenotype-specific approaches. An inhaler trial should have a target, technique review and an assessment of benefit; chronic antibiotics or steroids should not follow merely from the diagnosis of Sjögren. [R13]

Bronchiectasis makes infection history, sputum and airway clearance especially important when evaluating a proposed immune regimen. Conversely, attributing every new respiratory symptom to infection can delay recognition of inflammatory disease. The distinction is made by a coherent assessment, not by choosing one permanent explanation at the first visit.

Back to contents ↑

Kidneys: tubular dysfunction is not glomerulonephritis

Renal assessment needs more than a creatinine value. Potassium, bicarbonate, urine findings and the trajectory help identify tubular and glomerular problems. Distal renal tubular acidosis can cause clinically important potassium depletion and acid–base disturbance. Correcting these abnormalities is a direct treatment task and should not wait for a slow immune response. Severe symptomatic electrolyte disturbance may require acute care.

For active tubulointerstitial nephritis with impaired renal function, glucocorticoids and a selected steroid-sparing agent, commonly MMF in reported series, may be considered with nephrology. In the 12-patient biopsy-confirmed Evans series, treated patients showed improvement in renal measures, but there was no randomized control and concomitant treatment limits attribution. The finding supports a clinical option rather than a guarantee of recovery or proof that MMF is superior to alternatives. [R06]

The potentially reversible inflammatory component and established scarring affect expectations. Persistent tubular defects may still need replacement treatment after inflammation improves. Conversely, an apparent response in serum potassium does not prove that the interstitial inflammatory process is controlled.

Proteinuria, active urine sediment or otherwise unexplained renal decline may instead raise concern for a glomerular process. Biopsy, when indicated, can identify immune-complex disease or a competing diagnosis. Cryoglobulinemia, an associated connective tissue disease and monoclonal/clonal findings may redirect treatment. Do not import the TIN approach into every glomerular lesion, or assume that every kidney problem in Sjögren is autoimmune. [R01] [R02] [R06]

When a monoclonal component may be pathogenic, review the small-clone assessment.

Back to contents ↑

Blood counts, gland enlargement and lymphoma

A low cell count is a finding, not a mechanism. Consider medication toxicity, infection, deficiency, immune destruction, marrow disease and other relevant explanations. A stable mild abnormality and rapidly evolving clinically important cytopenia require different responses. Evidence of hemolysis, bleeding, severe neutropenia or broader systemic deterioration changes urgency and the involvement of hematology.

Selected immune cytopenias may need glucocorticoids or another immune-directed agent; the regimen follows the demonstrated condition. A falling count during treatment can be toxicity rather than uncontrolled Sjögren. Escalating the same therapy without examining that possibility can worsen the problem. [R01]

Persistent or asymmetric major-gland enlargement, a focal lesion or suspicious lymphadenopathy warrants directed evaluation. Neither dryness nor recurrent nonspecific swelling establishes lymphoma. If lymphoma is diagnosed, histological type, extent and clinical context determine management with hematology/oncology. Rituximab can appear in both autoimmune and lymphoma care, but that does not make the two treatment plans equivalent.

Where feasible and clinically appropriate, establish the tissue diagnosis before empiric treatment obscures a suspicious lesion. Urgent organ threats may require coordinated decisions before every result is available. The plan should document what is known, what remains uncertain and who is directing the next step. [R01] [R02]

Back to contents ↑

A drug comparison needs a clinical context
OptionWhy it may enter the discussionWhat must be resolved
HCQSelected inflammatory or systemic manifestationsIntended target; limits of symptom efficacy; dose and retinal-monitoring suitability
MTXSignificant inflammatory joint disease, including associated RAGenuine synovitis; renal/hepatic and reproductive context; medication safety
MMFSelected lung, renal or other organ-directed treatmentOrgan evidence and trajectory; blood counts, infection, gastrointestinal tolerance and pregnancy planning
AZASelected organ or steroid-sparing strategyRationale compared with alternatives; marrow/hepatic risk, relevant enzyme/genetic assessment and interactions
RituximabSelected severe systemic/B-cell-associated complicationsPhenotype-specific evidence, infection/HBV and immunoglobulin assessment, infusion and follow-up plan
CyclophosphamideSelected severe or refractory organ-threatening diseaseExpected benefit versus infection, marrow, bladder and gonadal burden; induction and exit strategy
IVIGSelected immune neuropathies and other specific indicationsCorrect phenotype; measurable outcome; renal, thrombotic and volume-related risks
NintedanibSelected progressive fibrotic ILDDocumented progression, tolerability and the continuing role of other treatments

This is a comparison of roles and decision points, not a complete contraindication list or a dosing chart. Some safety considerations depend on local prescribing standards. The number of drugs mentioned in a guideline does not establish an evidence-based ladder for every patient. [R01] [R03] [R04] [R05] [R10] [R11]

Back to contents ↑

Why negative rituximab trials do not settle every organ question

TRACTISS randomized 133 anti-Ro-positive patients and did not demonstrate benefit on its primary fatigue/oral-dryness outcome. That result matters when discussing routine symptom treatment. It should not be concealed by a biological effect or a favorable exploratory analysis. [R08]

The trial also did not establish whether rituximab is ineffective for every severe organ phenotype. The rationale for selected vasculitic nerve disease, for example, comes from a different clinical problem and evidence base reflected in current organ guidance. This is a reason to explain the indication carefully, not a license to dismiss negative trials whenever they are inconvenient. [R03]

A useful discussion identifies the proposed target, the direct evidence for it, the important extrapolation and the consequence of delaying treatment. Improvement in B-cell measurements is not itself the patient-important outcome. Repeated treatment should be linked to disease control, safety and the chosen clinical strategy rather than an isolated laboratory result.

For low immunoglobulins with recurrent infection, see when antibody replacement becomes a separate treatment decision.

Back to contents ↑

Combining medicines: biological logic needs clinical evidence

Combination therapy may aim to improve control, reduce steroid exposure or address more than one manifestation. Each purpose needs its own rationale. Adding another agent also adds interactions, monitoring, adherence burden and potentially infection risk. Mechanistic complementarity alone cannot determine the net benefit.

RepurpSS-II adds 2026 randomized evidence for LEF plus HCQ in selected systemically active Sjögren disease. Its small, single-center phase 2b population and 24-week assessment do not define a universal first-line regimen for every organ manifestation. The detailed target-and-response chapter presents its principal result and limitations. It should not be substituted for organ-specific evidence in rapidly progressive nerve or lung disease. [R09]

Likewise, evidence for a lung combination in a mixed CTD population must retain that population label. If more than one agent is started because the organ threat warrants it, document how response and toxicity will be attributed as far as possible. A later simplification plan is part of the initial decision, even if its timing cannot yet be fixed. [R04] [R05]

NECESSITY (ACR 2026 abstract LB15): 211 participants were randomized. Week-24 STAR responses were 24.3% with placebo, 54.4% with HCQ–MMF and 52.4% with HCQ–leflunomide (both p<0.001). Separation was significant in the high-symptom/low-activity cohort; comparisons in the smaller ESSDAI ≥5 cohort were nonsignificant (both p=0.13). CRESS differences were also nonsignificant. Serious adverse events occurred in 4.3%, 11.1% and 2.9%, respectively. [N04]

This preliminary result broadens the discussion beyond RepurpSS, while requiring full-report and safety review. Subgroup nonsignificance does not demonstrate absence of benefit or prove different treatment effects between cohorts. Select a defined target and monitoring plan before using a combination.

Back to contents ↑

Make the safety plan specific enough to use

The relevant safety assessment follows the actual regimen, cumulative exposure and patient context. Establish baseline organ function and blood counts; address infection history, screening and prevention appropriate to the proposed immune therapy. Hepatitis B status matters particularly when considering B-cell depletion; a normal liver enzyme result is not a substitute for determining that status. TB screening and Pneumocystis prevention depend on the treatment and risk context. [R10]

A plan should name who orders and reviews monitoring, which changes require earlier contact and how treatment interruptions will be handled. Retinal surveillance for HCQ is separate from ordinary dry-eye care. Immunoglobulin and infection history can influence repeat rituximab decisions. Kidney impairment affects more than the disease assessment: it can change the suitability or exposure of several symptom and immune treatments.

Pregnancy planning is drug-specific. HCQ, MTX, MMF and LEF cannot be grouped under a universal “rheumatology medicines” instruction. Maternal pregnancy, paternal exposure and breastfeeding have different evidence and restrictions. Advance planning aims to maintain disease control with an appropriate regimen rather than replace treatment with unplanned withdrawal. [R11]

Confirmed SSc overlap materially alters steroid risk. Integrate that concern into the treatment choice instead of treating ACA positivity itself as the diagnosis. Serious complications can require multidisciplinary balancing of risks; the relevant decision concerns the actual overlap phenotype. [R12]

For the combination of prior cryoglobulinemia and treatment-related antibody deficiency, see the immunoglobulin decision.

Back to contents ↑

Immunoglobulin for immune treatment is not the same decision as replacement

IVIG is not the default initial treatment for vasculitic neuropathy. Rare reports describe severe cutaneous vasculitis or acute cryoglobulinemic kidney injury after IVIG in patients whose monoclonal IgM had rheumatoid-factor activity. Added IgG may provide substrate for pathogenic immune complexes. These reports justify caution and specialist planning, not a claim that every patient with positive cryoglobulins must never receive immunoglobulin. [R03] [V10] [V11]

Later, after repeated B-cell depletion, the balance may change. An IgG of 3.1 g/L, recurrent significant infections and poor vaccine antibody responses warrants clinical-immunology assessment for antibody replacement. Review previous immunoglobulin levels, infection documentation, other causes of low IgG and the need for additional B-cell therapy. The UKPIN consensus supports considering replacement when IgG is below 4 g/L with poor vaccine responses, unless infection burden is low. Thresholds guide rather than dictate the decision. Vaccine testing needs clinical interpretation, including treatment timing; it should not become an automatic prerequisite that delays care in a seriously vulnerable patient. Choose IV or subcutaneous replacement, infection-prevention measures and monitoring together. In someone with prior cryoglobulinemic disease, include that history explicitly in the plan. [V12]

Back to contents ↑

Distinguish rescue, maintenance and reassessment

Rapid loss of organ function creates a different time horizon from a stable chronic symptom. Acute respiratory deterioration, rapidly evolving motor loss, severe symptomatic electrolyte disturbance or a clinically dangerous cytopenia requires prompt assessment and may require hospital-level care. Do not use the expected slow onset of a maintenance drug to justify waiting through deterioration.

After initial control, the questions change: what is still active, what recovery is plausible, how much is residual damage and which treatment burden can be reduced? Maintenance is not merely the indefinite continuation of induction. It needs a rationale, an outcome measure and a plan for recurrence or toxicity.

An adequate apparent treatment failure should trigger a review of diagnosis, exposure, mechanism and competing causes before indiscriminate escalation. However, reassessment should occur at a pace consistent with the organ risk. Protecting a threatened nerve or lung and investigating uncertainty can proceed together within specialist care. [R01] [R03] [R04] [R05]

Back to contents ↑

Clinical decisions that change when the phenotype is clarified

Painful hands, normal inflammatory examination. Do not equate symptom severity with DMARD failure. Establish whether the dominant problem is joint inflammation, tendon disease, structural pain or another mechanism. If synovitis is demonstrated later, the treatment question changes; an earlier noninflammatory examination should not become a permanent dismissal.

Burning feet versus new asymmetric foot drop. Both may be described as “neuropathy,” but the second presentation requires a more urgent localization and vasculitic assessment. A pain-medication response is not enough evidence that progressive nerve injury has stopped.

ILD progressing despite MMF. Confirm a genuine trajectory and adequate exposure; look for infection or a different pulmonary contributor. Reconsider the immune strategy and whether progressive fibrosis creates a role for an antifibrotic. An isolated cough increase does not by itself establish that sequence.

Low potassium with weakness and only modest creatinine change. Treat the immediate electrolyte risk and investigate tubular dysfunction. Do not conclude that the kidneys are uninvolved because filtration appears relatively preserved. Correction of potassium and treatment of active TIN answer different questions.

Persistent gland swelling before a proposed immune escalation. Identify whether there is a focal lesion requiring tissue evaluation. The same drug name can occur in autoimmune and oncologic care, but a diagnostic shortcut may obscure the condition that should determine the regimen.

These are original teaching situations, not patient records. Their purpose is to show how a better-defined lesion changes treatment—not to supply a personal prescription from a brief description.

Back to contents ↑

Sources

  1. [N01] Mariette et al. NEPTUNUS-1/-2: ianalumab phase III report (NEJM, October 2026)
  2. [N02] OASIZ-301: ACR 2026 abstract LB22
  3. [N03] argenx: UNITY discontinued for futility (8 October 2026)
  4. [N04] NECESSITY: ACR 2026 abstract LB15
  5. [R01] BSR adult and juvenile Sjögren disease guideline (2024/2025)
  6. [R02] EULAR topical and systemic Sjögren’s treatment recommendations
  7. [R03] Deboo et al. Peripheral nervous system manifestations in Sjögren’s: guideline (first published online 2025; 2026 issue)
  8. [R04] ERS/EULAR connective tissue disease-associated ILD guideline (first published online 2025; 2026 issue)
  9. [R05] 2023 ACR/CHEST Guideline for Treatment of ILD in Systemic Autoimmune Rheumatic Diseases (2024)
  10. [R06] Evans et al. Tubulointerstitial nephritis in primary Sjögren syndrome: manifestations and response to treatment (2016)
  11. [R07] Amlani et al. Treatment of primary Sjögren-related ILD: a retrospective cohort study (2020)
  12. [R08] Bowman et al. Rituximab for fatigue and oral dryness in primary Sjögren: TRACTISS randomized trial (2017)
  13. [R09] Leflunomide plus hydroxychloroquine in Sjögren disease: RepurpSS-II randomized placebo-controlled trial (2026)
  14. [R10] 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections (2023 issue)
  15. [R11] EULAR antirheumatic drugs in reproduction, pregnancy and lactation: 2024 update (2025)
  16. [R12] BSR systemic-sclerosis guideline (2024)
  17. [R13] Lee et al. Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren’s (2021)
  18. [V10] IVIG-associated cutaneous vasculitis in type II cryoglobulinemia: case report (2002).
  19. [V11] Acute cryoglobulinemic renal failure after IVIG: case report (1987).
  20. [V12] British Society for Immunology/UKPIN immunoglobulin replacement consensus (2022).

Personal educational publication by Olga Goodman, MD. This is not a clinic portal or an emergency service. Any private expert service is separate from clinic accounts and insurance billing. Reuse requires attribution and a link to the original publication.

dr.rheumaview.com · Olga Goodman, MD

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Medication safetySjögren diseaseTreatment decisions